Table 6.
Safety indices of familial hypercholesterolaemia subjects, initiated on pravastatin in childhood (aged 8–18 years) and treated for 10 years, compared with their unaffected siblings
| FH (n = 194) | Siblings (n = 83) | P-value | |
|---|---|---|---|
| Effect on liver function; no. (%) of patients | |||
| ↑ in AST >3 × ULN | 1 (0.5) | 1 (1.1) | 0.26 |
| ↑ in ALT >3 × ULN | 1 (0.5) | 0 | 0.51 |
| ↑ in CK >10 × ULN | 0 | 2 (2.1) | 0.03 |
| Effect on renal function | |||
| eGFR (mL/min/1.73 m2), median (IQR) | 127 (121–131) | 125 (119–130) | 0.05 |
| Diabetes, n (%) | 1 (0.5) | 1 (1.2) | 0.55 |
| C-reactive protein (mg/dL), median (IQR) | 0.9 (0.3–2.3) | 1.2 (0.3–3.0) | 0.27 |
| Age at menarche (year), mean (95% CI) | 13.1 (12.2–13.4) | 13.4 (12.8–14.1) | 0.27 |
| Level of education, n (%) | |||
| Lower | 31 (17.1) | 13 (16.0) | 0.96 |
| Middle | 71 (39.2) | 33 (40.7) | |
| Higher | 79 (43.6) | 35 (43.2) | |
Adapted from Kusters et al.98
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; CK, creatine kinase; eGFR, estimated glomerular filtration rate; IQR, interquartile range; ULN, upper limit of normal range.